Brainstorm cell therapeutics announces fda advisory committee meeting to review biologics license application for nurown® for the treatment of als

Conference call and webcast at 8:00 a.m. et new york , march 27, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the u.s. food and drug administration (fda) will hold an advisory committee meeting ('adcom') to discuss the company's biologics license application (bla) for nurown® for the treatment of amyotrophic lateral sclerosis (als).
BCLI Ratings Summary
BCLI Quant Ranking